The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 23 results:
Author Title Type [ Year(Asc)]
Filters: Author is Koutras, Angelos and Keyword is Middle Aged  [Clear All Filters]
2019
Kotoula, V., Tsakiri K., Koliou G-A., Lazaridis G., Papadopoulou K., Giannoulatou E., et al. (2019).  Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.. Clin Breast Cancer. 19(2), 113-125.e4.
2018
Christodoulou, C., Oikonomopoulos G., Koliou G. Angeliki, Kostopoulos I., Kotoula V., Bobos M., et al. (2018).  Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.. Cancer Genomics Proteomics. 15(6), 461-471.
Koutras, A., Lazaridis G., Koliou G-A., Kouvatseas G., Christodoulou C., Pectasides D., et al. (2018).  Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.. PLoS One. 13(12), e0207707.
2017
Psyrri, A., Kalogeras K. T., Wirtz R. M., Kouvatseas G., Karayannopoulou G., Goussia A., et al. (2017).  Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.. J Transl Med. 15(1), 30.
Zagouri, F., Kotoula V., Kouvatseas G., Sotiropoulou M., Koletsa T., Gavressea T., et al. (2017).  Protein expression patterns of cell cycle regulators in operable breast cancer.. PLoS One. 12(8), e0180489.
2016
Kotoula, V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., et al. (2016).  Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.. Breast Cancer Res Treat. 158(2), 307-21.
Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., et al. (2016).  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.. J Transl Med. 14(1), 136.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.
2015
Koutras, A., Kalogeras K. T., Wirtz R. M., Alexopoulou Z., Bobos M., Zagouri F., et al. (2015).  Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.. J Transl Med. 13, 171.
Pavlakis, K., Bobos M., Batistatou A., Kotoula V., Eleftheraki A. G., Stofas A., et al. (2015).  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.. Pathol Oncol Res. 21(2), 273-82.
2014
Lakis, S., Kotoula V., Eleftheraki A. G., Batistatou A., Bobos M., Koletsa T., et al. (2014).  The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.. Breast. 23(3), 234-43.
Pentheroudakis, G., Kotoula V., Kouvatseas G., Charalambous E., Dionysopoulos D., Zagouri F., et al. (2014).  Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.. Clin Breast Cancer. 14(5), 330-8.
Mountzios, G., Aivazi D., Kostopoulos I., Kourea H. P., Kouvatseas G., Timotheadou E., et al. (2014).  Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.. PLoS One. 9(3), e91407.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
2013
Fountzilas, G., Dafni U., Bobos M., Kotoula V., Batistatou A., Xanthakis I., et al. (2013).  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy.. BMC Cancer. 13, 163.
Fountzilas, G., Kotoula V., Pectasides D., Kouvatseas G., Timotheadou E., Bobos M., et al. (2013).  Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.. PLoS One. 8(7), e69256.
2012
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Pectasides, D., Papaxoinis G., Kotoula V., Fountzilas H., Korantzis I., Koutras A., et al. (2012).  Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.. Oncol Rep. 27(1), 216-24.
Korantzis, I., Kalogeras K. T., Papaxoinis G., Kotoula V., Koutras A., Soupos N., et al. (2012).  Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.. Anticancer Res. 32(10), 4569-80.
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
Fostira, F., Tsitlaidou M., Papadimitriou C., Pertesi M., Timotheadou E., Stavropoulou A. V., et al. (2012).  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.. Breast Cancer Res Treat. 134(1), 353-62.
Pectasides, D., Papaxoinis G., Kalogeras K. T., Eleftheraki A. G., Xanthakis I., Makatsoris T., et al. (2012).  XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.. BMC Cancer. 12, 271.
2011
Fountzilas, G., Kourea H. P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., et al. (2011).  Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.. Anticancer Res. 31(9), 3007-18.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.